INVIZA® Health headquarters in Cambridge, MA are makers of a cutting edge remote patient-personnel monitoring (RPM) platform called INVIZA® CARE M1.0, which is intended to be used to monitor patients in a Hospital-at-Home (HaH) setting and for the military/VA hospitals.  Our platform consists of [1] self-charging (from steps; walking, running, and exercise) smart insoles with clinically/highly accurate vital sign  sensors (HR, HRV, RR, SpO2, body temperature), body movement (for instance fall detection), and a location sensor (GPS); [2] a Secure IoT Operational Planning Environment (SIoTOPE) cloud platform with AI/machine learning (ML) and other analytics and data storage designed per Department of Defense (DoD) strategies and is HIPAA compliant; [3] a user mobile app with digital therapeutics (DTx) for health and fitness; and [4] a command / hospital / physician web portal to monitor numerous patients or military personnel simultaneously.

INVIZA’s primary market is the U.S. Air Force focusing initially on its Air Mobility Command (AMC, comprised of 110K pilots, crew and medical personnel of 330 total airmen). INVIZA was awarded an 18-month $2.3M commercialization contract from the U.S. Air Force Research Laboratory (AFRL) targeting the AMC.  Our goal is two-fold, first to monitor airmen for early illness and disease detection and second to track airmen performance or physical fitness

The Company’s secondary market is medical/HaH, rural health, assisted living facilities, retirement communities and VA hospitals.  INVIZA is currently working with a few HaH companies in the market segments mentioned.  Our FDA 510(k) application for our RPM/DTx platform will be filed in the summer 2025.